Autonomix faces Nasdaq bid-price compliance notice

Autonomix Medical, Inc. received a notice from Nasdaq that its common stock has failed to meet the minimum $1.00 per share bid price requirement for the last 30 consecutive business days, triggering a deficiency under Nasdaq’s continued listing rules.

Rhea-AI Filing Summary

Autonomix Medical, Inc. received a notice from Nasdaq that its common stock has failed to meet the minimum $1.00 per share bid price requirement for the last 30 consecutive business days, triggering a deficiency under Nasdaq’s continued listing rules.

The company has an initial 180-day grace period until July 13, 2026 to regain compliance by having its closing bid price at or above $1.00 for at least 10 consecutive business days. If it still falls short, Autonomix may qualify for a second 180-day period if it meets other Nasdaq Capital Market listing standards.

If compliance is not restored and no additional period is granted, Autonomix’s common stock may be delisted from Nasdaq, although the company could appeal. Management is monitoring the share price and may consider options such as a reverse stock split, but there is no assurance it will regain compliance.

Positive

• None.

Negative

• Nasdaq bid-price deficiency and delisting risk: Autonomix’s stock has traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a Nasdaq deficiency notice and creating the possibility of delisting if compliance is not regained by the stated deadlines.

Insights

Equity & Listing Standards Analyst

Nasdaq bid-price deficiency introduces real delisting risk for Autonomix.

Autonomix Medical, Inc. has fallen below Nasdaq’s $1.00 minimum bid price for 30 consecutive business days, triggering a formal deficiency under the Bid Price Rule. The company now has an initial 180-day window, until July 13, 2026, to restore its bid price to at least $1.00 for 10 consecutive business days.

If it meets all other initial listing standards, Autonomix could receive a second 180‑day compliance period, but failure to do so would allow Nasdaq Staff to initiate delisting, subject to appeal. The company explicitly mentions a potential reverse stock split as one option to cure the deficiency, highlighting that any path back to compliance may rely on corporate actions rather than trading momentum alone.

The filing underscores that there is no assurance of regaining compliance or of a successful appeal if delisting proceeds. For investors, this introduces uncertainty about future trading venue and liquidity, with key milestone dates centered on the current July 13, 2026 compliance deadline and any subsequent Nasdaq determinations.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Autonomix Medical (AMIX) receive a Nasdaq deficiency notice?

Autonomix Medical, Inc. received a Nasdaq deficiency letter because its common stock’s closing bid price was below the $1.00 per share minimum requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

How long does Autonomix (AMIX) have to regain Nasdaq bid-price compliance?

Autonomix has an initial 180-day grace period under Nasdaq Listing Rule 5810(c)(3)(A), giving the company until July 13, 2026 to regain compliance with the $1.00 bid price rule.

What must Autonomix Medical do to regain compliance with Nasdaq’s $1.00 bid price rule?

To regain compliance, Autonomix’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, after which Nasdaq Staff would provide written confirmation of compliance, subject to its discretion to extend that period.

Can Autonomix (AMIX) get more time beyond July 13, 2026 to meet Nasdaq rules?

If Autonomix is still below the $1.00 bid price by July 13, 2026, it may qualify for a second 180-day compliance period if it meets the market value of publicly held shares requirement and all other initial listing standards for the Nasdaq Capital Market, aside from the minimum bid price.

What happens if Autonomix Medical fails to regain Nasdaq compliance?

If Autonomix does not regain compliance and is not eligible for an additional period, Nasdaq Staff may notify the company that its common stock will be delisted. Autonomix would then be entitled to appeal this decision to a Nasdaq Listing Qualifications Panel, but success is not assured.

Is Autonomix considering a reverse stock split to address the Nasdaq bid-price issue?

Autonomix states it intends to monitor its closing bid price and may consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split, though there is no assurance it will regain compliance.

Does the Nasdaq deficiency letter immediately delist Autonomix Medical stock?

No. The company notes that the Nasdaq deficiency letter does not result in the immediate delisting of its common stock from the Nasdaq Capital Market; it initiates a compliance period during which the company can seek to cure the deficiency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/16/2026 - 07:30 AM Learn about SEC filing dates

false 0001617867 0001617867 2026-01-13 2026-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

Autonomix Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-41940	47-1607810
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

21 Waterway Avenue, Suite 300

The Woodlands, TX 77380

(Address of principal executive offices) (Zip Code)

s telephone number, including area code: (713) 588-6150

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share	AMIX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                                                                                                                          ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided an initial period of 180 calendar days, or until July 13, 2026 (the “Compliance Date”), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the closing bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H).

If the Company is not in compliance with the Bid Price Rule by July 13, 2026, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split.

If the Company does not regain compliance with the Bid Price Rule by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock may be delisted. The Company would then be entitled to appeal the Staff’s determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful.

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AUTONOMIX MEDICAL, INC.
	By:	/s/ Trent Smith
		Trent Smith
		Chief Financial Officer

Dated: January 16, 2026